CurrentUnitedHealthcarePolicy IEXD0063.08

Luxturna (Voretigene Neparvovec-Rzyl) — Medical Benefit Drug Policy

Medical benefit coverage criteria for Luxturna to treat inherited retinal dystrophy due to biallelic RPE65 mutations for UnitedHealthcare Individual Exchange plans (excludes MA, NV, NY).

Policy Summary

PayerUnitedHealthcare

PolicyLuxturna (Voretigene Neparvovec-Rzyl) — Medical Benefit Drug Policy

Policy CodePolicy IEXD0063.08

Change TypeRevised coverage criteria

Effective DateJan 1, 2026

Next Review Date

Key ActionObtain prior authorization; authorizations limited to one lifetime treatment per eye and valid for no more than 45 days from approval.

SourceLink

POLICY UPDATE CHANGES

Revised coverage criteria; added criterion requiring the provider does not request a planned inpatient admission for the sole purpose of administering Luxturna.

1 per eyeauthorization limit

>12 mominimum patient age

>100 µmminimum retinal thickness

J3398primary code

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical necessity (Initial treatment)

Covered when ALL of the following are met:

Age: Patient is greater than 12 months of age.
Diagnosis of a confirmed biallelic RPE65 mutation-associated retinal dystrophy (e.g., Leber's congenital amaurosis, retinitis pigmentosa, early onset severe retinal dystrophy).
Genetic confirmation: Genetic testing documenting biallelic mutations of the RPE65 gene.
Viable retina: Sufficient viable retinal cells as determined by optical coherence tomography (OCT) confirming an area of retina within the posterior pole of > 100 µm thickness.
Provider qualifications: Prescribed and administered by an ophthalmologist or retinal surgeon with experience providing sub-retinal injections.
Prior treatment: Patient has not previously received Luxturna (voretigene neparvovec-rzyl) gene therapy in the intended eye.
Inpatient admission: Provider does not request a planned inpatient admission for the sole purpose of administering Luxturna.
Authorization limits: Prior authorization is obtained; authorization will be issued for no more than one treatment per lifetime per eye and for no longer than 45 days from approval.

Treatment with Luxturna is not recommended for patients younger than 12 months of age. The FDA-labeled rationale is that retinal cells in this age group are still undergoing proliferation, and administration of the gene therapy at that time could result in the therapeutic vector being diluted or lost during ongoing cell division.

Any use of voretigene neparvovec-rzyl that does not meet all of the specified coverage criteria in this policy is considered not medically necessary and is not covered. This includes, but is not limited to, failure to meet the minimum age requirement, lack of documented biallelic RPE65 pathogenic variants, absence of sufficient viable retinal cells by OCT, treatment by an unqualified provider, previous receipt of therapy in the intended eye, or requests that contravene authorization limits.

Coding

Procedure / HCPCSHCPCS

J3398

Injection, voretigene neparvovec-rzyl, 1 billion vector genomes.

Diagnosis / ICD-10ICD-10

H35.50	Unspecified hereditary retinal dystrophy
H35.52	Pigmentary retinal dystrophy
H35.54	Dystrophies primarily involving the retinal pigment epithelium

inv-06: OCT retinal thickness

OCT retinal thickness threshold> 100 µm in area of the posterior pole (indicates sufficient viable retina)

Measurement methodOptical coherence tomography (OCT) confirming an area of retina within the posterior pole >100 µm thickness

Documentation requirementOCT report must demonstrate posterior pole area >100 µm thickness and be included in prior authorization submission

inv-07: Minimum patient age

Minimum eligible age> 12 months of age

ReasoningTreatment is not recommended for patients younger than 12 months because retinal cells are still undergoing proliferation and treatment may be diluted or lost

Physician assessmentTreating physician must confirm patient age in documentation for prior authorization

Provider Actions & Administrative Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required. Authorization is limited to one lifetime treatment per eye and approvals are valid for up to 45 days from the date of approval.

J3398: injection, voretigene neparvovec-rzyl (reference code)
Authorization limit: 1 lifetime treatment per eye
Authorization duration limit: ≤ 45 days from approval

Note

Benefit Considerations

Benefit coverage decisions must be made using the member-specific benefit plan document and applicable state mandates. Some plans or state laws may require coverage for off-label or experimental/investigational treatments for serious or life‑threatening conditions; where state mandates apply, they supersede policy language. Refer to the Policy and Procedure for treatment of serious rare diseases when considering coverage exceptions.

Consult member-specific Certificate of Coverage for allowance of experimental/investigational treatments
State mandates may require coverage and supersede policy terms
Benefit determinations are subject to the member’s plan and applicable laws

Documentation Required

Required Documentation

Providers must submit documentation to support medical necessity, including genetic testing confirming biallelic RPE65 mutations, ophthalmic imaging (OCT) demonstrating sufficient viable retinal cells (area within posterior pole > 100 µm thickness), diagnostic documentation of RPE65-associated retinal dystrophy, and evidence of provider qualifications and informed consent. Include clinical history, prior treatments, laterality, and notation that the patient has not previously received Luxturna in the treated eye.

Genetic testing report documenting biallelic RPE65 mutations
OCT imaging demonstrating >100 µm retinal thickness in treatment area
Clinical diagnosis (e.g., LCA, RP, EOSRD) and laterality
Provider qualifications: ophthalmologist/retinal surgeon experienced in sub‑retinal injections
Documentation of informed consent and treatment plan
Statement that patient has not previously received Luxturna in the intended eye

Denial Risk

Inpatient Admission for Sole Purpose of Administration

Requests for planned inpatient admission solely for the purpose of administering Luxturna may be disallowed. Authorization should reflect outpatient/sub‑procedure setting unless there is clinical justification for inpatient admission unrelated to the administration itself.

Planned inpatient admission for the sole purpose of Luxturna administration is not routinely authorized
If inpatient admission is requested, submit clinical justification unrelated to administration (e.g., comorbid conditions requiring inpatient care)

Definitions

inv-13: Viable retinal cells

DefinitionPresence of sufficient functional retinal cells as determined by OCT confirming an area of retina within the posterior pole >100 µm thickness

Clinical importanceGene therapy does not create new retinal cells; benefit requires existing viable, post-mitotic retinal cells

Assessment methodOptical coherence tomography (OCT) measurement of retinal layer thickness; treating physician may also assess viability clinically

inv-14: Biallelic RPE65 mutation-associated retinal dystrophy

Diagnostic requirementGenetic testing documenting biallelic RPE65 mutations must be provided for coverage

FDA indication noteLuxturna is indicated for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy; treating physician must determine retinal cell viability

Background

Leber’s congenital amaurosis (LCA) and autosomal recessive retinitis pigmentosa (RP) are inherited early-onset retinal dystrophies that can result from biallelic pathogenic variants in the RPE65 gene. RPE65 deficiency impairs the visual cycle by reducing production of 11-cis retinal, leading to progressive photoreceptor dysfunction. Voretigene neparvovec-rzyl (Luxturna) is an adeno-associated virus vector–based gene augmentation therapy designed to restore RPE65 function and improve visual function when administered while sufficient retinal cells remain viable. The therapy is intended as a one-time subretinal administration for appropriately selected patients who meet genetic, age, and retinal viability criteria.